| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8659300 | European Journal of Vascular and Endovascular Surgery | 2018 | 7 Pages |
Abstract
f/b EVAR in high risk patients offers similar 2 year mortality to OSR performed in lower risk patients but at a higher cost. The cost is mainly driven by the cost of the stent graft, which is not compensated for by lower healthcare resource consumption. Further studies are necessary to evaluate the cost-effectiveness in low risk f/b EVAR patients who may experience fewer complications.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Morgane Michel, Jean-Pierre Becquemin, Jean Marzelle, Céline Quelen, Isabelle Durand-Zaleski, the WINDOW Trial participants the WINDOW Trial participants,